



TargeGen Announces Successful Completion of Patient Enrollment In Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients And Scheduled Presentation of Preliminary Trial Data At EHA Conference in Berlin

San Diego, CA – May 14, 2009 - TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009.

The current clinical trial is being conducted at six centers in the USA. The study enrolled 28 patients in the dose-escalation phase (completed in February 2009) and 31 patients in the dose-confirmation phase of the study (currently in progress). Primary goals of this open-label study included identification of a maximum tolerated dose (MTD) in the dose-escalation phase and accumulation of safety data, assessments of drug effect on surrogate markers, biomarkers, and presumptive clinical endpoints in both phases of the study. Preliminary trial data presented at the 2008 ASH conference indicated that the drug was well tolerated and exhibited dose-dependant reductions of splenomegaly and leukocytosis. Updated clinical data pertaining to this trial are scheduled for presentation at the European Hematology Association (EHA) conference on June 6, 2009 in Berlin.

About TargeGen, Inc.

TargeGen, Inc. is a privately held biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors for applications in oncology and inflammatory diseases.

For additional information, contact: TargeGen, Inc.
9380 Judicial Drive
San Diego, CA 92121
Tel 858-678-0760
Fax 858-678-0160
info@targegen.com
www.targegen.com

--end--